Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy
- Substances:AnastrozoleCamizestrant+6
Austria- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:AstraZeneca AB
Rare diseases
Investigational molecules
Locations
Back to Austria4 clinical trials in Kufstein, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.
AustriaStudy on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen
AustriaStudy on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer
AustriaStudy of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma
AustriaThe busiest research cities in the country
What the registry says about research in the country
Innovative studies focusing on hormone receptor-positive (HR+)/HER2-negative breast cancer treatments, evaluating new therapeutic approaches for improved patient outcomes.
These trials aim to enhance standard endocrine therapy effectiveness in early-stage breast cancer treatment.
Research investigating treatments for seasonal allergic rhinitis and rhinoconjunctivitis, specifically targeting birch pollen-induced allergies.
Clinical evaluations focus on developing effective interventions for seasonal allergy symptoms.
Studies examining innovative treatments for newly diagnosed multiple myeloma in elderly patients, focusing on combination therapies.
Investigations aim to improve treatment outcomes for elderly patients through targeted combination therapies.
Tell us about your condition – we search every trial in Europe and connect you with the right site.